Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustatin GM2 and NPC patients, is now fully enrolled
Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustatin GM2 and NPC patients, is now fully enrolled
Read MoreAzafaros’ Phase 2 RAINBOW study, evaluating nizubaglustatin GM2 and NPC patients, is now fully enrolled
Read MorePHILADELPHIA, Aug. 07, 2023 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic…
Read More